These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31033054)

  • 1. Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk.
    Sheng J; Shen L; Sun L; Zhang X; Cui R; Wang L
    Cell Prolif; 2019 May; 52(3):e12609. PubMed ID: 31033054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coptisine induces autophagic cell death through down-regulation of PI3K/Akt/mTOR signaling pathway and up-regulation of ROS-mediated mitochondrial dysfunction in hepatocellular carcinoma Hep3B cells.
    Kim SY; Hwangbo H; Kim MY; Ji SY; Lee H; Kim GY; Kwon CY; Leem SH; Hong SH; Cheong J; Choi YH
    Arch Biochem Biophys; 2021 Jan; 697():108688. PubMed ID: 33227289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
    Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J
    J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
    J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
    Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
    J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL; Lee BS; Lin LI; Liou JY; Liao SC; Hsu C; Cheng AL
    Mol Cancer; 2014 Jan; 13():2. PubMed ID: 24387108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of DRP1‑mediated mitophagy increases the apoptosis of hepatocellular carcinoma cells in the setting of chemotherapy.
    Ma M; Lin XH; Liu HH; Zhang R; Chen RX
    Oncol Rep; 2020 Mar; 43(3):1010-1018. PubMed ID: 32020220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
    Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
    Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells.
    Yao N; Li YJ; Lei YH; Hu N; Chen WM; Yao Z; Yu M; Liu JS; Ye WC; Zhang DM
    J Exp Clin Cancer Res; 2016 Dec; 35(1):192. PubMed ID: 27931237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
    Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
    Xie Z; Wang J; Liu M; Chen D; Qiu C; Sun K
    PLoS One; 2017; 12(3):e0173252. PubMed ID: 28334043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.